Business Context and Reporting Period
Company: Protalix Biotherapeutics, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: January 13, 2008
Reporting Period: Event date January 13, 2008; Press release issued January 14, 2008.
Context: The Company entered into a material definitive lease agreement to expand its manufacturing and research facility in Carmiel, Israel.
Key Financial Metrics
This filing does not report revenue, profit, cash flow, margins, debt, or liquidity metrics. The only financial data provided relates to the new lease agreement:
- Base Rent: Approximately $300,000 per year for the additional space.
- Rent Adjustments: Subject to monthly adjustments based on the Israeli Consumer Price Index.
- Extension Rent Increase: 10% increase upon exercise of any extension option.
Material Changes
The primary material change is the expansion of physical capacity:
- Space Expansion: The new lease provides approximately three times the Company's current manufacturing space.
- Location: Expansion is within the existing facility in Carmiel, Israel.
- Counterparty: Lease entered with Engel Science Parks (99) Ltd.
Guidance, Outlook, and Terms
Lease Terms:
- Initial Term: 7.5 years.
- Extension Options: Three options to extend, each for a five-year period (aggregate of 15 additional years).
Management Commentary: The filing indicates the Company is scaling its manufacturing capabilities. No specific financial guidance or risk factors beyond the standard lease obligations were detailed in this specific text.
Investor Verification Checklist
- Verify the total capital expenditure required to fit out the additional manufacturing space.
- Confirm the Company's current cash position to support the $300,000 annual rent increase and associated operational costs.
- Review the full text of the Lease Agreement (Exhibit 10.1, referenced but not included in this summary) for termination clauses or specific performance guarantees.
- Assess the timeline for when the expanded capacity will become operational and contribute to revenue.